Assistance with developing small-molecule drugs

Provided by: Drug Innovation Ventures at Emory (DRIVE), LLC
 
Who’s eligible: Emory researchers working on small molecule anti-viral or anti-cancer therapies (especially cancers of a viral etiology)
 
If your early-stage, small-molecule drug to fight viruses or cancer is promising — but you need expertise to develop it with those who have done so before — contact DRIVE.
 
An independent LLC wholly owned by Emory, DRIVE is an industry experienced team working with a select number of Emory scientists interested in developing their active molecules to a suitable “value inflection point” for:

• licensure by a company or
• launching a new start-up.

DRIVE’s counsel covers all aspects of drug development up to Phase 2a, as well as developing an associated market, IP and business strategy.
 
DRIVE also will license the molecule for development within Emory and work collaboratively with you on drug development and value creation.
 
DRIVE is the company behind the discovery and development of:

• EIDD-2801/molnupiravir, the leading oral antiviral therapy for COVID-19 (licensed to Merck);

• EIDD-2173, which was licensed to Antios Therapeutics and was the basis of a $96 million series B financing in April 2021.